{"id":672427,"date":"2023-10-16T18:34:02","date_gmt":"2023-10-16T18:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=672427"},"modified":"2023-10-16T18:34:02","modified_gmt":"2023-10-16T18:34:02","slug":"onychomycosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-hallux-pfizer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/onychomycosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-hallux-pfizer_672427.html","title":{"rendered":"Onychomycosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies &#8211; Hallux, Pfizer"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Onychomycosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Hallux, Pfizer \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Onychomycosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Hallux, Pfizer \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Onychomycosis Market Insights, Epidemiology, and Market Forecast \u2013 2032\u2019 report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/onychomycosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Onychomycosis Market Insights, Epidemiology, and Market Forecast &ndash; 2032<\/a><\/strong>&rsquo; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Companies working on Onychomycosis&nbsp; Disease include Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, and many others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Therapies included in the Onychomycosis&nbsp; Disease market include Itraconazole, Terbinafine,&nbsp; MOB015B, Terbinafine HCl, and many others&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The onychomycosis market size was approximately USD 2,900 million in 2021.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Onychomycosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Onychomycosis is a fungal nail infection that causes discoloration and thickening of the affected nail plate. It was initially caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by non-dermatophyte molds (NDMs) are more prevalent, especially in warmer climates. Onychomycosis caused by dermatophytes is called tinea unguium. The term Onychomycosis encompasses not only dermatophytes but also yeasts and saprophytic mold infections. It can infect both fingernails and toenails, Onychomycosis of the toenail is more prevalent. Onychomycosis is classified into subtypes based on the invasion pattern. Distal subungual onychomycosis (DSO) is the most common subtype and occurs when the fungus invades the distal aspect of the nail plate. In superficial white onychomycosis (SWO), fungi invade the most superficial layers of the nail plate.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/384ae3a5db1d41b5c0f0999153c7970f.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Onychomycosis Disease Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The diagnosed prevalence of onychomycosis population in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China was estimated to be close to 121,608,000 cases in 2021.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/onychomycosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Onychomycosis Disease Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;<\/strong><strong>The Report Covers the Onychomycosis&nbsp; Disease Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Onychomycosis prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Onychomycosis incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Onychomycosis treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Onychomycosis diagnosed cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Onychomycosis Disease Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There is only one approved therapy for Onychomycosis in the market, namely, PROGLYCEM (diazoxide) &#8211; a non-diuretic benzothiadiazine derivative used for the management of symptomatic hypoglycemia. Proglycem capsules and suspension are manufactured by IVAX Pharmaceuticals and Teva Pharmaceuticals, respectively; the suspension was manufactured for Gate Pharmaceuticals, a division of Teva Pharmaceuticals.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">A number of children with Onychomycosis are partially or completely unresponsive to diazoxide. Second-line treatment with other agents such as octreotide\/lanreotide, is required in such children. Somatostatin receptor analogs (SSRAs), typically octreotide\/lanreotide, which inhibit insulin release, are preferred as second-line treatment in diazoxide-unresponsive patients. The use of SSRAs is off-label as only diazoxide is approved for CHI. Octreotide reduces insulin release by decreasing the insulin gene promoter activity, inhibiting voltage-dependent calcium channels and adenylyl cyclase activity. Long\u2010acting SSRAs are favored by families on account of the monthly injection regimen without recourse to daily injections as needed for octreotide therapy. One problem with using a long\u2010acting SSRA is the inability to reduce the dose, unlike with oral preparations such as diazoxide. Given that severity of CHI may naturally reduce over time, the use of fixed\u2010dose long\u2010acting SSRAs may be considered disproportionate.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Onychomycosis (CHI) market in 7MM is expected to witness a major change in the study period 2019&ndash;2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&nbsp;Key Companies Working in the Onychomycosis Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Moberg Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Blueberry Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hallux,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bausch Health&nbsp;&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Onychomycosis Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Itraconazole&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Terbinafine<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MOB015B<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Terbinafine HCl,&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/onychomycosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Key Companies and Emerging Therapies in the Onychomycosis Disease Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Onychomycosis&nbsp; Disease&nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Executive Summary of Onychomycosis&nbsp; Disease&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Onychomycosis&nbsp; Disease&nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Onychomycosis&nbsp; Disease&nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/onychomycosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Onychomycosis Disease Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=onychomycosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-hallux-pfizer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=onychomycosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-hallux-pfizer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Onychomycosis Market Insights, Epidemiology, and Market Forecast \u2013 2032\u2019 report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of onychomycosis in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/onychomycosis-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-hallux-pfizer_672427.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-672427","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/672427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=672427"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/672427\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=672427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=672427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=672427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}